The NGAL Test* for BN Systems*
The BN NGAL Test - The First Choice Biomarker to Support the detection of Acute Kidney Injury (AKI).
BioPorto Diagnostics is proud to announce that our NGAL Test now has been exclusively designed for use on BN Systems.
Acute kidney injury (AKI) is a global burden, with more than 13 million incidents per year and a high mortality rate. To address this a specific marker for the detection of AKI: a neutrophil gelatinase-associated lipocalin (NGAL) Test is now offered by Siemens Healthineers. One of the most upregulated proteins, with a fast response after only 2–4 hours following AKI, NGAL is an ideal marker for clinical settings.
Adding NGAL into a clinical routine can significantly accelerate the diagnosis of AKI, allowing early treatment for better patient outcomes. The ready-to-use NGAL Test* for BN Systems* complements the comprehensive kidney menu available on the BN(TM)II and BN Prospec(R)Systems. Learn more.
* NGAL Test is a trademark of BioPorto Diagnostics A/S. BN and BN Prospec are trademarks of Siemens Healthcare Diagnostics Products GmbH, or its affiliates. All other trademarks are the property of their respective owners.